A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH

CARE Pharma

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Hemolysis; PNH

Treatments: Drug: CAN106 40 mg/kg; Drug: CAN106 20 mg/kg; Drug: CAN106 80 mg/kg

Study type: Interventional

Funder types: Industry

Identifiers

NCT05539248

CTR20220162 (Registry Identifier)

CAN106-PNH-102/201

Details and patient eligibility

About

The purpose of the study is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of CAN106 administered intravenously to subjects with PNH who have not previously been treated with a complement inhibitor.

Full description

This is an open-label, multiple dose escalation study to assess the safety, tolerability, efficacy, PK, PD and immunogenicity of CAN106 given as an IV infusion. The data presented is up to the primary completion date of the study and is for the 26-week primary evaluation period. The study also includes an extension period of up to 52 weeks.

Enrollment: 78 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female patients ≥18 years of age.
2. Body weight ≥40 kg at screening.
3. Documented diagnosis of PNH within 6 months prior to screening, confirmed by high-sensitivity flow cytometry evaluation of red blood cells (RBCs), with granulocyte or monocyte clone size of ≥10%.
4. LDH level ≥ 1.5 X ULN at screening.
5. Mean hemoglobin(Hb)<10 g/dL for those who have not received blood. transfusion at screening, based on 2 measurements from separate blood samples collected at interval of 2-8 weeks apart prior to the first dosing. Or hemoglobin < 10 g/dL at the first screening and then with subsequent red blood cell transfusions.
6. Presence of 1 or more of the following PNH-related signs or symptoms within 3 months of Screening: fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), anemia (hemoglobin < 10 g/dL), history of a major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction; or history of pRBC transfusion due to PNH.
7. All patients must be vaccinated against meningococcal infections within 3 years prior to, or at the time of, initiating study drug. Patients who initiate study drug treatment less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination.
8. If available, Haemophilus influenzae type b and Streptococcus pneumoniae vaccines can be administered according to national vaccine guidelines, and antibiotic prophylaxis should be given until 2 weeks after vaccination if the vaccines are administered within 14 days prior to administration.
9. All females of childbearing potential and all males must be willing to use at least one highly effective method of contraception from signing of informed consent until 8 months after the last dose of CAN106 Injection; Male subjects with female partners of childbearing potential must be willing to use condoms in addition to using a highly effective method of contraception.
10. Subjects should be willing to sign the informed consent forms and comply with the study visit.

Exclusion criteria

1. Current or previous treatment with a complement inhibitor.

2. Positive pregnancy test on day 1, or female patients who are planning to become pregnant or are pregnant or breastfeeding.

3. Participation in an interventional clinical study within 28 days before initiation of dosing on Day 1, or within 5 half-lives of the investigational product, whichever is greater.

4. Platelet count < 30 × 10^9/L at Screening.

5. Absolute neutrophil count < 0.5 × 10^9/L at Screening.

6. Alanine aminotransferase (ALT) > 3 × ULN, or both direct bilirubin and alkaline phosphatase (ALP) > 2 × ULN during the screening period.

7. Serum creatinine > 2.5 × ULN and creatinine clearance < 30 mL/min as calculated by the Cockcroft-Gault formula during the screening period.

8. History of malignancy within 5 years of Screening with the exception of nonmelanoma skin cancer or carcinoma in situ of the cervix that has been treated with no evidence of recurrence.

9. History of bone marrow transplantation.

10. Major surgery within 90 days prior to screening.

11. History of N. meningitidis infection or unexplained, recurrent infection.

12. Known or suspected hereditary complement deficiency.

13. Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing

14. Presence of fever ≥38°C within 7 days prior to study drug administration.

15. Having received splenectomy within 6 months prior to screening.

16. Known history of severe allergic or anaphylactic reactions to antibiotics and are unwilling to use prophylaxis as specified in the protocol.

17. Patients are excluded if they are taking any of the following medications and are not on a stable regimen(as judged by investigator) for the time period indicated prior to screening:

    1. Erythropoietin or immunosuppressants for at least 8 weeks;
    2. Corticosteroids for at least 4 weeks;
    3. Vitamin K antagonists with a stable international normalized ratio for 4 weeks;
    4. Iron supplements or folic acid for at least 4 weeks;
    5. Low molecular weight heparin for at least 4 weeks.

18. Known allergy to excipients of CAN106 or allergy to Chinese hamster ovary cell proteins.

19. Immunization with a live-attenuated vaccine 1 month prior to dosing on day 1.

20. Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to the start of Screening.

21. Inability to comply with study requirements.

22. History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease (eg, active hepatitis) that, in the opinion of the Investigator or Sponsor, precludes the patient's participation in an investigational clinical trial.

23. Known medical or psychological condition(s) or risk factor that, in the opinion of the Investigator, might interfere with the patient's full participation in the study, pose any additional risk for the patient, or confound the assessment of the patient or outcome of the study.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

78 participants in 3 patient groups

Dose escalation CAN106 in cohort 1

Experimental group

Description:

Subjects are administered CAN106 20 mg/kg IV maintenance dosing.

Treatment:

Drug: CAN106 20 mg/kg

Dose escalation CAN106 in cohort 2

Experimental group

Description:

Subjects are administered CAN106 40 mg/kg IV maintenance dosing.

Treatment:

Drug: CAN106 40 mg/kg

Dose escalation CAN106 in cohort 3

Experimental group

Description:

Subjects are administered CAN106 80 mg/kg IV maintenance dosing.

Treatment:

Drug: CAN106 80 mg/kg